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Background: Bronchial airflow limitation is a known predictor of raised C-reactive protein
(CRP) level. The aim of this study was to explore this association in an elderly population,
as well as the influence of other known and possible predictors of the CRP level, like
smoking and the use of statins and inhaled corticosteroids.
Population and methods: The study population consists of 3877 Norwegians aged 60 years
or more who took part in the fifth Tromsø study in 2001, a cross-sectional study. The
examinations included questionnaires, spirometry and the measurement of CRP.
Results: A geometric mean CRP value of 3.15mg/L was found in subjects with severe
airflow limitation (FEV1%o50 predicted and FEV1/FVCo70%), compared to 1.64mg/L in
subjects with normal spirometry, (po0.001), and 19% of the subjects with severe airflow
limitation had a CRP value above 10mg/L compared to 4.9% in those with mild airflow
limitation or normal spirometry. Elevated body mass index (BMI), smoking, hormone
replacement therapy, and increasing age, were also strong independent predictors of
increased CRP. Statin use was a strong predictor of decreased CRP level, while the use of
inhaled corticosteroids was not associated with decreased CRP values.
Conclusion: We found a strong link between bronchial airflow limitation and the
circulating CRP level in an elderly population, independent of self-reported diseases,
medication, smoking, and elevated BMI. The CRP value increased with increasing age in
men, but not in women, which may be partly explained by a greater impact of chronicElsevier Ltd. All rights reserved.
44816; fax: +47 776 44831.
.uit.no (H. Melbye).
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H. Melbye et al.2542obstructive pulmonary disease (COPD) morbidity on the CRP level in men than in women.
Measuring CRP may show to be a useful part of the diagnostic work-up in COPD patients.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is character-
ized by inflammatory changes in all segments of the
bronchial tree,1 which can be traced by, among other
biomarkers, the circulating C-reactive protein (CRP). Among
COPD patients, raised CRP values are particularly found in
severe cases,2–5 and in patients with frequent exacerba-
tions.6 Increased CRP values are not only associated with the
degree of bronchial airflow limitation,7–10 but also predict
bad prognosis in COPD patients.11,12 Cigarette smoking is a
known predictor of raised CRP level, but can only partly
explain the association between the CRP level and the
severity of airflow limitation.5,10 COPD is an established risk
factor of myocardial infarction, and since elevated CRP
predicts cardiovascular events,7,13,14 CRP has been sug-
gested to be a link between these conditions.15
The use of oral or inhaled corticosteroids has been shown
to reduce the CRP level in COPD patients,5,16 and reduces
the frequency of exacerbations in severe disease.17 There is
also evidence of a favourable effect of inhaled corticoster-
oids in COPD patients in terms of reduced risk of
cardiovascular death.18 Statins reduce both CRP level and
mortality in subjects with cardiovascular disease.19 The
effect of statins on the inflammatory response in COPD is
still unknown.
In this population-based study, we registered daily
medication, smoking, and self-reported diseases in addition
to spirometry and body mass index (BMI), and CRP was
measured with high sensitive method. The aim was to
explore how the CRP level, in an elderly population, is
associated with bronchial airflow limitation when analysed
together with this wide range of factors affecting the
inflammatory response.Methods
Subjects
The participants were inhabitants of Tromsø aged 60 years
or more, who took part in a population survey between
March 2001 and February 2002. The Tromsø Study is a
repeated population-based study in the municipality of
Tromsø, a city in the northern part of Norway, with a current
population of 64,000. This fifth Tromsø Study was conducted
by Institute of Community Medicine, University of Tromsø in
cooperation with the National Health Screening Service. In
the fourth survey in 1994, all inhabitants aged 55–74 years
of age, and 5–10% of samples in other age groups between 25
and 84 years, were asked to take part in a second, and more
extensive medical examination (phase II). The attendance
rate was 77%. In this fifth survey, all phase II participants
from the fourth survey who still lived in Tromsø, were
eligible to participate. In addition, all inhabitants aged 60and 75 years were invited. A total of 5328 subjects aged 60
years or more were eligible and 4713 (88.5%) attended phase I,
and 4519 (85%) attended also phase II. Spirometry was
performed in 4102 subjects, 90% of the attendees and 77%
of those eligible for participation. Absence of staff and
technical problems were reasons for spirometry not being
performed in 10% of the attendees. At the time of data
analysis, 54 subjects had withdrawn their consent to
participate. Ninety women and 21 men (2.7% of all) were
excluded due to inadequate spirometry.20 Of the 3938
remaining subjects, CRP measurement was obtained in
3877 (72.8% of all eligible), and these were included in our
analyses.Examinations
A questionnaire including smoking habits, previous diseases,
and daily medication was enclosed in the letter of invitation
and collected at the following visit, where height and
weight were measured. Participants who reported to be
suffering from asthma and chronic bronchitis, were classi-
fied as ‘‘self-reported asthma’’ and ‘‘self-reported chronic
bronchitis/emphysema’’, respectively, and they were
grouped together as ‘‘self-reported obstructive lung dis-
ease’’. Those reporting angina pectoris, myocardial infarc-
tion or cerebral stroke, were classified as ‘‘self-reported
cardiovascular disease’’.
The brand names of prescribed drugs used regularly
during the 4 weeks preceding the study were reported and
registered on the fifth level of the Anatomical Therapeutic
Chemical (ATC) system, version 2000. Participants reporting
a proprietary name of a statin (ATC group C10AA) were
classified as statin users in the analysis. Use of inhaled and
systemic corticosteroids were defined from self-report of
brand names belonging to ATC groups R03BA, and R03AK,
and H02AB, respectively. Participants reporting use of
antihypertensive treatment, were classified as users of
antihypertensives, regardless of reported brand names.
Use of systemic estrogens (hormone replacement therapy,
HRT) was only to be reported by women.
When attending the first examination, the participants
got a second questionnaire, which should be submitted by
post or delivered when they met for the phase II examina-
tion a few weeks later. One of the questions addressed
recent airway infection: ‘‘Have you, during the last 3 weeks,
had a common cold, a flu, bronchitis, pneumonia, sinusitis or
other airway infection?’’
Spirometry, carried out with the use of a ‘‘Sensormedics
Vmax 20’’, was part of the phase II examination. The
American Thoracic Society-criteria for spirometry testing
were followed.21 Reversibility test was not performed.
Current drug therapy was not interrupted before the test.
The European Community of Steel and Coal (ECSC)22
equations were used in the calculation of % predicted
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basis of lung function: severe airflow limitation: FEV1/
FVCo70% and FEV1% predictedo50 (corresponding to GOLD
stages 3 and 4), moderate airflow limitation; FEV1/
FVCo70% and FEV1% predicted X50 and o80 (correspond-
ing to GOLD stage 2), mild airflow limitation: FEV1/
FVCo70% and FEV1% predicted X80% (corresponding to
GOLD stage 1), pulmonary restriction: FEV1/FVCX70% and
FEV11% predicted o80, and normal airflow: FEV1/FVCX70%
and FEV11% predicted X80.
On the examination day blood was drawn for CRP analysis.
Sera were stored at 20 1C until tested. CRP was measured
by high (ultra) sensitive CRP method (particle-enhanced
immuno-turbidimetric assay) in MODULAR P auto-analyser
(Roche/Hitachi) with reagents from Roche Diagnostics
GmbH, Mannheim, Germany. The analytical sensitivity
(lower detection limit) of this assay is 0.03mg/L, and the
measuring range is 0.1–20mg/L. The analytical coefficient
of variation (CV) is 3.6%. The samples with CRP more than
5mg/L were analysed by immunoturbidometric method
within the same analyser and with reagents from the same
manufacturer. The analytical sensitivity (lower detection
limit) of the assay is 3mg/L, and the analytical CV is 4.0%.
Statistical analysis
The CRP values were analysed according to gender, age,
smoking habit, spirometry results, BMI, self-reported dis-
eases, and medication. Differences between groups were
analysed using Mann–Whitney’s and w2 tests. Pearsons’
correlation was calculated between the CRP level and other
continuous variables. Because CRP values were skewed,
geometric means were calculated, and explanatory vari-
ables were entered multivariable linear regression analysis
with log-CRP as the outcome variable. The SPSS 12.0 for
Windows (SPSS Inc., Chicago, Illinois, USA) was used in the
statistical analyses. A p-value o0.05 was considered
significant. The Regional Committee for Medical Research
Ethics in North Norway approved the Tromsø V survey. All the
participants gave written informed consent.
Results
Mean age in the study material was 69.4 years, and 54.1% of
the 3877 included subjects were women. Among women,
47.2% were never smokers, compared to 18.2% among the
men (Table 1). BMI fell significantly with increasing age in
men (r ¼ 0.154, po0.001), while a weak positive correla-
tion, statistically insignificant, was found in women.
Moderate or severe airflow limitation was more frequently
detected in men than in women, in 17.8% and 12.7%,
respectively (po0.001), and this sex-difference was
particularly pronounced among the subjects older than
70 years (Table 1). Cardiovascular disease was reported
almost twice as often in men than in women, while there
were only small differences in self-reported obstructive lung
disease and diabetes. Severe and moderate airflow limita-
tion was found in 3% and 12%, respectively. The correspond-
ing frequencies were 13% and 30% among those who
reported asthma, and 18% and 25% when chronic bronchitis
was reported.CRP by gender, age, and life-style
CRP values ranged from 0.12 to 220mg/L, the mean value
was 3.58mg/L, the median value 1.66mg/L, whereas the
geometric mean was 1.81mg/L. No significant difference in
geometric mean CRP value was observed between men and
women (Table 2). A significant correlation between age and
CRP level was found for men (r ¼ 0.072, po0.005), but not
for women (r ¼ 0.003, NS). Current smokers had signifi-
cantly higher CRP values than previous smokers, and CRP
values were highly increased, with a geometric mean of
2.59mg/L in subjects with BMI higher than 30 kg/m2 (Table 2).
CRP by lung function and reported diseases
Moderate to severe airflow limitation and pulmonary
restriction were associated with increased CRP values, and
the geometric mean was 3.15mg/L in severe airflow
limitation (Table 2). In this subgroup, 18.9% had a CRP value
above 10mg/L (Figure 1). In the subjects with normal
spirometry or mild airflow limitation the frequency was
significantly lower, 4.9% (po0.001). Self-reported obstruc-
tive lung disease, cardiovascular disease, diabetes, and
recent airway infection were all associated with increased
CRP values (Table 2).
CRP and medication
Use of antihypertensive medication was associated with
increased CRP values (Table 2). Among the 512 subjects
who reported obstructive lung disease, 172 used inhaled
corticosteroids. The geometric mean CRP in these 172 was
2.55mg/L, compared to 2.26mg/L in the 340 non-users (a
non-significant difference). Oral corticosteroids were used in
23 of the subjects who reported obstructive lung disease.
Their geometric mean CRP value was 1.99mg/L, compared to
2.37 in the 489 non-users (po0.001). Among the oral
corticosteroid users who did not report obstructive lung
disease the geometric mean CRP was 5.15mg/L. Significantly
increased CRP values were detected in women who used HRT.
Statin use was associated with decreased CRP values. This
was particularly the case in subjects who reported cardio-
vascular disease, but not obstructive lung disease, 1.54 and
2.30mg/L, in users and non-users, respectively (po0.001,
Table 3). When both cardiovascular and chronic lung diseases
were reported, the CRP values did not differ significantly
between users and non-users of statins (Table 3).
CRP in healthy subjects
The geometric mean CRP value was 1.26mg/L in the 646
subjects who were never smokers, had a BMIo30, had not
reported chronic respiratory or cardiovascular disease,
diabetes, or recent airway infection, and were not using
oral corticosteroids.
Multivariate analysis
By multivariate analysis, age, male gender, smoking, BMI,
diabetes, recent airway infection and use of HRT and oral
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Table 1 Characteristics of the 3887 study subjects according to gender and age.
n Women Men
60–69
years
70 years + All 60–69
years
70 years + All
n % n % n % n % n % n %
Smoking habit
Never smoker 1300 478 43.5 501 51.3 979 47.2 195 20.7 126 15.3 321 18.2
Previous smoker 1647 320 29.1 296 30.3 616 29.7 502 53.3 529 64.0 1031 58.3
Current daily smoker 896 300 27.3 180 18.4 480 23.1 245 26.0 171 20.7 416 23.5
Body mass indexy
o30 kg/m2 3044 860 77.5 721 73.9 1581 75.8 759 80.7 704 85.1 1463 82.7
X30 kg/m2 809 249 22.5 255 26.1 504 24.2 182 19.3 123 14.9 305 17.3
Lung functionz
Normal, FEV1/FVCX70% and
FEV1% predicted X80
2558 822 73.9 633 64.8 1455 69.7 666 70.8 437 52.8 1103 62.4
Restriction, FEV1/FVCX70% and
FEV1% predicted o80
332 98 8.8 87 8.9 185 8.9 73 7.8 74 8.9 147 8.3
Mild airflow limitation (GOLD 1) 388 73 6.6 111 11.4 184 8.8 83 8.8 121 14.6 204 11.5
Moderate airflow limitation
(GOLD 2)
463 106 9.5 115 11.8 221 10.6 92 9.8 150 18.1 242 13.7
Severe airflow limitation
(GOLD 3+4)
116 13 1.2 31 3.2 44 2.1 27 2.9 45 5.4 72 4.1
Self-reported disease
Asthma 385 112 10.1 116 11.8 228 10.9 73 7.7 84 10.1 157 8.8
Chronic bronchitis/emphysema 224 66 5.9 62 6.3 128 6.1 40 4.2 56 6.7 96 5.4
Any obstructive lung disease 512 151 13.6 145 14.7 296 14.1 99 10.5 117 14.1 216 12.1
Cardiovascular disease 801 118 10.6 200 20.3 318 14.2 209 22.1 274 32.9 483 27.2
Diabetes 190 43 3.9 55 5.6 98 4.7 47 5.0 45 5.4 96 5.4
Recent airway infection 535 164 14.7 110 11.2 274 13.1 143 15.1 118 14.2 261 14.7
Self-reported medication
Antihypertensives 1093 252 22.6 336 34.1 588 28.0 237 25.0 268 32.2 505 28.4
Inhaled corticosteroids 186 47 4.2 49 5.0 96 4.6 37 3.9 53 6.4 90 5.1
Oral corticosteroids 76 14 1.3 24 2.4 38 1.8 16 1.7 22 2.6 38 2.1
Hormone replacement therapy 202 18.1 80 8.1 282 12.7
Statins 535 142 12.7 116 11.8 258 12.3 151 15.9 126 15.1 277 15.6
The Tromsø Study 2001.
Information about smoking habit was missing in 34 subjects.
yBMI measurement was not available in 24 subjects.
zTwenty subjects not classified due to missing height.
H. Melbye et al.2544corticosteroids, were significant predictors of increased CRP
values, whereas increasing FEV1% predicted and use of
statins were associated with decreased CRP values (Table 4).
Multivariate analyses excluding the subjects who reported
recent airway infection, gave similar results, but cardiovas-
cular disease became a significant predictor (po0.05),
whereas previous smoking turned out to be an insignificant
predictor.Discussion
We observed a strong association between reduced bron-
chial airflow and increased circulating CRP level among
elderly subjects. Among subjects with severe airflowlimitation, as many as 19% had a CRP value above 10mg/L,
in line with a population based study including younger
individuals.8 The sensitivity of the CRP measurement, with a
lower detection limit of 0.03mg/L, made possible more
valid geometric means than in the study by Mannino et al.8
As described in previous studies, BMI,7,23 current smok-
ing,5,10 and use of systemic oestrogens24 were strong
predictors of raised CRP values, and added to the effect of
airflow limitation. Interestingly, self-reported cardiovascu-
lar disease did not turn out to be an important independent
predictor of elevated CRP level in the multivariate analyses,
although controlled for statin use in the model.
The reduced CRP values among the statin users, com-
pared with non-users, were comparable to reductions found
in clinical trials with statins in patients with cardiovascular
ARTICLE IN PRESS
Table 2 CRP values by gender, age, smoking habit, body mass index, lung function, self-reported diseases, and medication in
3877 subjects aged 60 years or more.
n CRP (mg/L)
(geometric mean)
p-Value
All 3877 1.81
Gendery
Women 2098 1.76
Men 1779 1.87 NS
Age
60–69 years 2061 1.72
X70 years 1816 1.92 0.001
Smoking habitz
Never smoker 1300 1.59
Previous smoker 1647 1.83 o0.001y
Current daily smoker 896 2.11 o0.001z
Body mass indexJ
o30 kg/m2 3044 1.64
X30 kg/m2 809 2.59 o0.001
Lung function
Normal, FEV1/FVCX70% and FEV1% predicted X80 2558 1.64
Restriction, FEV1/FVCX70% and FEV1% predicted o80 332 2.50 o0.001yy
Mild airflow limitation (GOLD 1) 388 1.74 NSyy
Moderate airflow limitation (GOLD 2) 463 2.21 o0.001yy
Severe airflow limitation (GOLD 3+4) 116 3.15 o0.001yy
Self-reported diseasezz
Asthma
Yes 385 2.34
No 3492 1.76 o0.001
Chronic bronchitis/emphysema
Yes 224 2.42
No 3653 1.78 o0.001
Any obstructive lung disease
Yes 512 2.35
No 3365 1.74 o0.001
Cardiovascular disease
Yes 801 1.98
No 3076 1.77 o0.005
Diabetes
Yes 190 2.57
No 3687 1.78 o0.001
Recent airway infection
Yes 535 2.14 o0.001
No 3342 1.76 o0.001
Self-reported medicationyy
Antihypertensives
Yes 1093 2.03
No 2784 1.73 o0.001
Inhaled corticosteroids
Yes 186 2.53
No 3691 1.78 o0.001
Oral corticosteroids
Yes 76 3.86
No 3801 1.78 o0.001
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Table 2 (continued )
n CRP (mg/L)
(geometric mean)
p-Value
Hormone replacement therapy (only women)
Yes 282 2.16
No 1816 1.71 o0.001
Statins
Yes 535 1.59
No 3342 1.85 o0.001
The Tromsø Study 2001.
p-Values show statistical significance of differences between subgroups (Mann–Whitney’s test).
yWomen and men are compared.
zInformation about smoking habit was missing in 34 subjects.
yWhen compared with never smokers.
zWhen compared with previous smokers.
JBMI measurement was not available in 24 subjects.
Twenty subjects not classified due to missing height.
yyWhen compared to subjects with normal spirometry.
zzThose with and without the self-reported diseases are compared.
yyUsers and non-users of the medications are compared.
Figure 1 Distribution of CRP values by lung function* in 3857 subjects aged 60 years or more. The Tromsø Study 2001. (*Normal
spirometry: FEV1/FVCX70% and FEV1% predicted X80; pulmonary restriction: FEV1/FVCX70% and FEV1% predicted o80; mild
airflow limitation: FEV1/FVCo70% and FEV1% predicted X80% (GOLD stage 1); moderate airflow limitation: FEV1/FVCo70% and
FEV1% predictedX50% ando80% (GOLD stage 2); severe airflow limitation: FEV1/FVCo70% and FEV1% predictedo50% (GOLD stages
3 and 4)).
H. Melbye et al.2546disease.25–27 The decreased CRP level associated with statin
use in those who reported both obstructive lung disease and
cardiovascular disease or only obstructive lung disease did
not reach statistical significance. Probably, there is no such
strong effect of statins on inflammation linked to COPD, as
has been demonstrated in cardiovascular disease. A reduced
mortality in COPD patients who use statins has been found in
a recent study.28 The reduction found was not necessarily
associated with statin effects on the inflammatory response
in COPD, but may be explained by a very high prevalence of
cardiovascular disease, known and unknown, in COPD
patients.28 With this strong tendency of co-morbidity in
mind, the low frequency of statin use in subjects with self-
reported obstructive lung disease (Table 3) seems to be a
clinical challenge.
It was surprising that the use of inhaled corticosteroids
was not associated with decreased CRP level, not even whencontrolled for the degree of airflow limitation by multi-
variate analyses. Inhaled corticosteroids are recommended
in patients with severe COPD and frequent exacerbations,29
and CRP values have been found to be particularly increased
in this subgroup.6 Pinto-Plata et al. found significantly
reduced CRP levels associated with inhaled corticosteroid
use in an observational study of patients with severe COPD.5
In a small-sized placebo-controlled clinical trial, Sin et al.
found a striking effect of a daily dose of 1mg of fluticasone
on the CRP level among COPD patients among whom also
patients with moderate and mild disease were included.16
One may speculate if the drug use in our study was
associated with lower doses and compliance as compared
to the clinical trials. Possibly, prescriptions of inhaled
corticosteroid are associated with an increased severity of
COPD beyond what can be measured by the spirometry, with
higher CRP values previous to treatment than in those not
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Table 3 CRP-value by self-reported obstructive lung disease, self-reported cardiovascular disease, and statin use in 3877
subjects aged 60 years or more.
Using statins Not using statins All
n CRP (mg/L)
(geometric
mean)
n CRP (mg/L)
(geometric
mean)
n CRP (mg/L)
(geometric
mean)
Self-reported obstructive lung disease
combined with self-reported
cardiovascular disease
48 2.29 71 2.41 119 2.40
Self-reported obstructive lung disease,
but no self-reported cardiovascular
disease
16 1.89 377 2.36 393 2.34
Self-reported cardiovascular disease,
but not self-reported obstructive lung
disease
308 1.54y 374 2.30 682 1.92
The Tromsø Study 2001.
The difference between statin users and non-users is not statistically significant.
yThe difference between statin users and non-users is statistically significant, po0.001.
Table 4 Independent predictors of log-CRP (mg/L)
determined by linear multivariate regression in 3819
subjects aged 60 years or more.
Standardized
beta
p-Value
Subject characteristics
Male gender 0.04 o0.05
Age (years) 0.06 o0.001
Current smoker (y/n) 0.14 o0.001
Previous smoker (y/n) 0.04 o0.05
Self-reported disease (y/n)
Any obstructive lung
disease
0.01 NS
Cardiovascular disease 0.03 NS
Diabetes 0.03 o0.05
Recent airway infection 0.05 o0.005
Findings
FEV1% predicted 0.14 o0.001
Body mass index (kg/m2) 0.27 o0.001
Self-reported medication (y/n)
Antihypertensives 0.02 NS
Inhaled corticosteroids 0.01 NS
Oral corticosteroids 0.10 o0.001
Hormone replacement
therapy
0.07 o0.001
Statins 0.10 o0.001
Subjects with missing data about smoking, BMI, or FEV1%
predicted have been excluded.
Association of bronchial airflow limitation, smoking, body mass index, and statin use with the C-reactive protein level 2547treated with inhaled corticosteroids. Cross-sectional studies
cannot demonstrate effects of interventions.
The use of oral corticosteroids was a strong predictor of
raised CRP value. This can be explained by the use of thismedication in other diseases than COPD, such as rheumatoid
arthritis, ankylosing spondyloarthritis, and inflammatory
bowel diseases, in which the CRP value often is ele-
vated.30,31 Among those who reported obstructive lung
disease, however, use of oral corticosteroids was associated
with reduced CRP values.
A greater influence of age on the CRP level in men than in
women was also reported by Albert et al.24 Our findings
indicate different causes of increased CRP values in the two
genders. The age dependency in men is probably linked to a
greater increase in prevalence and severity of COPD with
increasing age. The effect of smoking probably increases by
age, since the number of pack-years have shown to play a
role,32 and among the women ever smoking and HRT use
became less frequent by increasing age (Table 1). The
similar average CRP values found in men and women, in
spite of the higher frequency of cardiovascular disease and
moderate to severe airflow limitation in men, can probably
be explained by both the use of HRT24 and the generally
higher BMI values in woman than in men. Severe co-
morbidity may have been a reason for non-participation in
the survey, and the effect of age could thus have been
somewhat underestimated.
As could be expected, a report of recent airway infection
had a significant influence on the CRP level. This association
was probably underestimated for two reasons. The partici-
pants were asked to report an airway infection that had
taken place within the last 3 weeks. The CRP response lasts,
however, usually not more than 14 days,33,34 and a
considerable proportion had probably reached their back-
ground CRP level when the blood was drawn. In addition, an
unknown proportion of the participants answered the
questionnaire several days before the blood sample was
drawn. Some participants may therefore have experienced
airway infection after answering the questionnaire, but
prior to the blood sampling. Nevertheless, the prevalence of
CRP values above 10mg/L in severe airflow limitation, tells
us that moderate elevated CRP values in exacerbations of
ARTICLE IN PRESS
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marker of bacterial infection,35 and that knowledge about
the background CRP value in COPD patients may be useful in
that respect.
The ECSC reference values were used. Application of
Norwegian reference values, which give higher estimates,
would have resulted in a higher percentage of FEV1%
predicted values below 80%. The Norwegian reference
values developed by Langhammer and co-workers may,
however, be too strict for our elderly population.20 In the
multivariate regression analysis, the choice of reference
values is of no importance. Somewhat higher values of FEV1/
FVC% and FEV1% predicted could have been obtained if
reversibility testing had been performed, but probably with
only a small effect on the association between spirometry
and CRP values. The similar CRP results in those with mild
bronchial obstruction (GOLD 1) and normal spirometry
support the view that the GOLD criterion of FEV1/FVCo70%
for diagnosing COPD may lead to misclassification of healthy
elderly.20
We have shown that impaired lung function is a strong
predictor of circulating CRP in the elderly, also when
controlling for other known predictors. The CRP value
reflects the severity of COPD, and CRP measurements may
show to be a useful part of the diagnostic work-up in COPD
patients, not only during exacerbations. This may be
obvious, if favourable effect of anti-inflammatory drugs on
both CRP level and clinical outcome can be shown.
Treatment effects of inhaled corticosteroids and statins on
the CRP level and prognosis in COPD patients need to be
studied further in clinical trials.Conflict of interest statement
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